Monday, September 10, 2018 10:35:45 PM
‘Theralase filed an ITA application with Health Canada on July 29, 2016. On September 16, 2016, Theralase received a formal response, which consisted of a series of 6 questions from Health Canada seeking additional information on the ITA application.
Theralase compiled a comprehensive written response on September 23, 2016 and it was received by Health Canada on September 26, 2016.
Health Canada has indicated that they require approximately 45 days to review the written response and as a result Theralase is not expecting a formal response from Health Canada until mid November 2016.
Theralase expects final ITA approval at this time, but Health Canada possesses the ability to ask additional questions, either as a clarification request, resulting in an additional 10 day review or request new information resulting in an additional 45 day review.
Pending Health Canada approval of the ITA, Theralase will immediately commence enrollment of patients into a Phase Ib clinical study in the treatment of NMIBC. ‘
ITA Approval granted on the 20th of October 2016
http://www.stockhouse.com/companies/bullboard?symbol=tltff&postid=28590944
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM